Last reviewed · How we verify
AbobotulinumtoxinA Injectable Product
AbobotulinumtoxinA Injectable Product, marketed by the University of Utah, holds a position in the therapeutic market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | AbobotulinumtoxinA Injectable Product |
|---|---|
| Also known as | Dysport |
| Sponsor | University of Utah |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (PHASE4)
- A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity (PHASE3)
- A Real-World Study on Effect of Hirudoid on Ecchymosis After Treatment of Crow's Feet With Botulinum Toxin Type A (PHASE4)
- Botulinum Toxin Versus Platelet Rich Fibrin for TMJ Internal Derangement (NA)
- A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101) (PHASE3)
- Exercise to Improve Sleep and Quality of Life in Stroke Patients Receiving Botulinum Toxin Treatment (NA)
- Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery (NA)
- OnabotulinumtoxinA for Trigeminal Neuralgia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AbobotulinumtoxinA Injectable Product CI brief — competitive landscape report
- AbobotulinumtoxinA Injectable Product updates RSS · CI watch RSS
- University of Utah portfolio CI